 ,Sr,Therapy Area,Condition,Molecule,Route of Administration,Country,Participants,Services,Sub Services,Channel,Adoption,Program Measure,Program benefit vs non-program,Source
0,1,Cancer-Haemtology,"Multiple Myeloma, Myelodysplastic Syndrome, Erythema Nodosum Leprosum","Lenalidomide, Thalidomide",Oral,USA,1000,Financial,Co-pay,Telephone,35.0,Perc_Dispensed Rx,,https://doi.org/10.2146/ajhp110383
1,1,Cancer-Haemtology,"Multiple Myeloma, Myelodysplastic Syndrome, Erythema Nodosum Leprosum","Lenalidomide, Thalidomide",Oral,USA,1000,Financial,Insurance support,Telephone,28.0,Perc_Dispensed Rx,,https://doi.org/10.2146/ajhp110383
2,1,Cancer-Haemtology,"Multiple Myeloma, Myelodysplastic Syndrome, Erythema Nodosum Leprosum","Lenalidomide, Thalidomide",Oral,USA,1000,Financial,Free-Supply,Telephone,15.0,Perc_Dispensed Rx,,https://doi.org/10.2146/ajhp110383
3,1,Cancer-Haemtology,"Multiple Myeloma, Myelodysplastic Syndrome, Erythema Nodosum Leprosum","Lenalidomide, Thalidomide",Oral,USA,1000,Financial,Co-pay,Telephone,35.0,Time-to-Initiation_days,,https://doi.org/10.2146/ajhp110383
4,1,Cancer-Haemtology,"Multiple Myeloma, Myelodysplastic Syndrome, Erythema Nodosum Leprosum","Lenalidomide, Thalidomide",Oral,USA,1000,Financial,Insurance support,Telephone,28.0,Time-to-Initiation_days,,https://doi.org/10.2146/ajhp110383
5,1,Cancer-Haemtology,"Multiple Myeloma, Myelodysplastic Syndrome, Erythema Nodosum Leprosum","Lenalidomide, Thalidomide",Oral,USA,1000,Financial,Free-Supply,Telephone,15.0,Time-to-Initiation_days,,https://doi.org/10.2146/ajhp110383
6,2,Cancer,"Neuroendocrine tumours, Acromegaly",Octreotide,IV,Australia,129,Patient Education,Nurse/AHP assistance,Inperson,,PREM: Satisfaction_Positiv_Impact,,https://doi.org/10.1111/ajco.13477
7,2,Cancer,"Neuroendocrine tumours, Acromegaly",Octreotide,IV,Australia,129,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PREM: Satisfaction_Positiv_Impact,,https://doi.org/10.1111/ajco.13477
8,2,Cancer,"Neuroendocrine tumours, Acromegaly",Octreotide,IV,Australia,129,Medicine Usage Support,Infusion (home),Inperson,,PREM: Satisfaction_Positiv_Impact,,https://doi.org/10.1111/ajco.13477
9,2,Cancer,"Neuroendocrine tumours, Acromegaly",Octreotide,IV,Australia,129,Medicine Usage Support,Testing,-,,PREM: Satisfaction_Positiv_Impact,,https://doi.org/10.1111/ajco.13477
10,2,Cancer,"Neuroendocrine tumours, Acromegaly",Octreotide,IV,Australia,129,Medicine Logistics,Home Delivery/Order,-,,PREM: Satisfaction_Positiv_Impact,,https://doi.org/10.1111/ajco.13477
11,3,Cancer,Prostate cancer,NA,NA,Australia,75,Patient Education,Website,Website,,PREM: Recommend,,https://doi.org/10.1016/j.invent.2014.10.001
12,3,Cancer,Prostate cancer,NA,NA,Australia,75,Medicine Routine,Reminders,Email/SMS/Mail,,PREM: Recommend,,https://doi.org/10.1016/j.invent.2014.10.001
13,3,Cancer,Prostate cancer,NA,NA,Australia,75,Psychosocial-Emotional,Psychological Intervention,Website,,PREM: Recommend,,https://doi.org/10.1016/j.invent.2014.10.001
14,3,Cancer,Prostate cancer,NA,NA,Australia,75,Psychosocial-Emotional,Patient communities-support,Website,,PREM: Recommend,,https://doi.org/10.1016/j.invent.2014.10.001
15,3,Cancer,Prostate cancer,NA,NA,Australia,75,Patient Education,Website,Website,,PROM: DASS-21_normal,,https://doi.org/10.1016/j.invent.2014.10.001
16,3,Cancer,Prostate cancer,NA,NA,Australia,75,Medicine Routine,Reminders,Email/SMS/Mail,,PROM: DASS-21_normal,,https://doi.org/10.1016/j.invent.2014.10.001
17,3,Cancer,Prostate cancer,NA,NA,Australia,75,Psychosocial-Emotional,Patient communities-support,Website,,PROM: DASS-21_normal,,https://doi.org/10.1016/j.invent.2014.10.001
18,3,Cancer,Prostate cancer,NA,NA,Australia,75,Patient Education,Website,Website,,PROM: IIEF_Overall_Score,,https://doi.org/10.1016/j.invent.2014.10.001
19,3,Cancer,Prostate cancer,NA,NA,Australia,75,Medicine Routine,Reminders,Email/SMS/Mail,,PROM: IIEF_Overall_Score,,https://doi.org/10.1016/j.invent.2014.10.001
20,3,Cancer,Prostate cancer,NA,NA,Australia,75,Psychosocial-Emotional,Psychological Intervention,Website,,PROM: IIEF_Overall_Score,,https://doi.org/10.1016/j.invent.2014.10.001
21,3,Cancer,Prostate cancer,NA,NA,Australia,75,Psychosocial-Emotional,Patient communities-support,Website,,PROM: IIEF_Overall_Score,,https://doi.org/10.1016/j.invent.2014.10.001
22,4,Diabetes,Diabetes,Insulin glargine,SC,Australia,514,Patient Education,Nurse/AHP assistance,Inperson,,FBG_achieved_control,,https://doi.org/10.1016/j.invent.2014.10.001
23,4,Diabetes,Diabetes,Insulin glargine,SC,Australia,514,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,FBG_achieved_control,,https://doi.org/10.1016/j.invent.2014.10.001
24,4,Diabetes,Diabetes,Insulin glargine,SC,Australia,514,Medicine Usage Support,Dose/inj training,Inperson,,FBG_achieved_control,,https://doi.org/10.1016/j.invent.2014.10.001
25,4,Diabetes,Diabetes,Insulin glargine,SC,Australia,514,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,FBG_achieved_control,,https://doi.org/10.1016/j.invent.2014.10.001
26,5,Diabetes,Diabetes,NA,NA,Australia,198,Patient Education,Nurse/AHP assistance,Inperson,,FBG_relative_change,300.0,https://doi.org/10.1016/j.invent.2014.10.001
27,5,Diabetes,Diabetes,NA,NA,Australia,198,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,FBG_relative_change,300.0,https://doi.org/10.1016/j.invent.2014.10.001
28,5,Diabetes,Diabetes,NA,NA,Australia,198,Patient Education,Partner Orgs,Partner Orgs,,FBG_relative_change,300.0,https://doi.org/10.1016/j.invent.2014.10.001
29,5,Diabetes,Diabetes,NA,NA,Australia,198,SideEffects/Comobidities Support,AHPs services,Inperson,,FBG_relative_change,300.0,https://doi.org/10.1016/j.invent.2014.10.001
30,5,Diabetes,Diabetes,NA,NA,Australia,198,Motivation/Confidence,Coaching/Counseling,Inperson,,FBG_relative_change,300.0,https://doi.org/10.1016/j.invent.2014.10.001
31,5,Diabetes,Diabetes,NA,NA,Australia,198,Motivation/Confidence,ICP,Inperson,,FBG_relative_change,300.0,https://doi.org/10.1016/j.invent.2014.10.001
32,5,Diabetes,Diabetes,NA,NA,Australia,198,Patient Education,Nurse/AHP assistance,Inperson,,BMI_relative_change,700.0,https://doi.org/10.1016/j.invent.2014.10.001
33,5,Diabetes,Diabetes,NA,NA,Australia,198,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,BMI_relative_change,700.0,https://doi.org/10.1016/j.invent.2014.10.001
34,5,Diabetes,Diabetes,NA,NA,Australia,198,Patient Education,Partner Orgs,Partner Orgs,,BMI_relative_change,700.0,https://doi.org/10.1016/j.invent.2014.10.001
35,5,Diabetes,Diabetes,NA,NA,Australia,198,SideEffects/Comobidities Support,AHPs services,Inperson,,BMI_relative_change,700.0,https://doi.org/10.1016/j.invent.2014.10.001
36,5,Diabetes,Diabetes,NA,NA,Australia,198,Motivation/Confidence,Coaching/Counseling,Inperson,,BMI_relative_change,700.0,https://doi.org/10.1016/j.invent.2014.10.001
37,5,Diabetes,Diabetes,NA,NA,Australia,198,Motivation/Confidence,ICP,Inperson,,BMI_relative_change,700.0,https://doi.org/10.1016/j.invent.2014.10.001
38,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Carer Enablement,,Telephone (Nurse/AHP),,Adherence_Rx_filled,21.0,https://doi.org/10.1007/s12325-021-01768-w
39,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_Rx_filled,21.0,https://doi.org/10.1007/s12325-021-01768-w
40,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_Rx_filled,21.0,https://doi.org/10.1007/s12325-021-01768-w
41,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,SideEffects/Comobidities Support,AHPs services,Inperson,,Adherence_Rx_filled,21.0,https://doi.org/10.1007/s12325-021-01768-w
42,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,SideEffects/Comobidities Support,AHPs services,Telephone (Nurse/AHP),,Adherence_Rx_filled,21.0,https://doi.org/10.1007/s12325-021-01768-w
43,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Financial,-,Telephone,,Adherence_Rx_filled,21.0,https://doi.org/10.1007/s12325-021-01768-w
44,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Carer Enablement,,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,9.0,https://doi.org/10.1007/s12325-021-01768-w
45,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Patient Education,Nurse/AHP assistance,Inperson,,Perc_discontinuation_12mnth,9.0,https://doi.org/10.1007/s12325-021-01768-w
46,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,9.0,https://doi.org/10.1007/s12325-021-01768-w
47,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,SideEffects/Comobidities Support,AHPs services,Inperson,,Perc_discontinuation_12mnth,9.0,https://doi.org/10.1007/s12325-021-01768-w
48,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,SideEffects/Comobidities Support,AHPs services,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,9.0,https://doi.org/10.1007/s12325-021-01768-w
49,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Financial,-,Telephone,,Perc_discontinuation_12mnth,9.0,https://doi.org/10.1007/s12325-021-01768-w
50,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,21.0,https://doi.org/10.1007/s12325-021-01768-w
51,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence_12mnth,21.0,https://doi.org/10.1007/s12325-021-01768-w
52,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,21.0,https://doi.org/10.1007/s12325-021-01768-w
53,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,SideEffects/Comobidities Support,AHPs services,Inperson,,Perc_Persistence_12mnth,21.0,https://doi.org/10.1007/s12325-021-01768-w
54,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,SideEffects/Comobidities Support,AHPs services,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,21.0,https://doi.org/10.1007/s12325-021-01768-w
55,12,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Nintedanib,,USA,3114,Financial,-,Telephone,,Perc_Persistence_12mnth,21.0,https://doi.org/10.1007/s12325-021-01768-w
56,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Carer Enablement,,Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
57,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Medicine Usage Support,Drug administration,Inperson,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
58,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Medicine Routine,Reminders,Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
59,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Medicine Logistics,Home Delivery/Order,-,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
60,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Patient Education,Help-line (non-clinical),Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
61,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Effective HCP Appointments,Patient care coordination,Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
62,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Financial,Co-pay,Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
63,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Financial,Insurance support,Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
64,18,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Infliximab,IV,Canada,10000,Financial,Free-Supply,Telephone,90.0,PREM: IV Perception_rating,60.0,https://lsc-pagepro.mydigitalpublication.com/publication/?m=38924&i=380838&view=articleBrowser&article_id=2701091&ver=html5
65,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Carer Enablement,,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
66,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Inperson,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
67,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
68,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Usage Support,Dose/inj training,Inperson,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
69,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Home Delivery/Order,-,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
70,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Disposal,-,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
71,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Routine,Reminders,Telephone,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
72,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Co-pay,Telephone,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
73,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Insurance support,Telephone,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
74,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Free-Supply,Telephone,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
75,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Motivation/Confidence,Coaching/Counseling,Inperson,,Perc_discontinuation_12mnth,46.0,https://doi.org/10.1016/j.clinthera.2018.02.001
76,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
77,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
78,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
79,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
80,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Home Delivery/Order,-,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
81,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Disposal,-,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
82,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Routine,Reminders,Telephone,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
83,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Co-pay,Telephone,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
84,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Insurance support,Telephone,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
85,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Free-Supply,Telephone,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
86,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Motivation/Confidence,Coaching/Counseling,Inperson,,Perc_Persistence_12mnth,30.0,https://doi.org/10.1016/j.clinthera.2018.02.001
87,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Carer Enablement,,Telephone (Nurse/AHP),,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
88,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
89,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
90,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
91,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Home Delivery/Order,-,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
92,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Disposal,-,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
93,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Routine,Reminders,Telephone,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
94,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Co-pay,Telephone,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
95,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Insurance support,Telephone,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
96,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Free-Supply,Telephone,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
97,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Motivation/Confidence,Coaching/Counseling,Inperson,,Adherence_MPR_gr80%,11.0,https://doi.org/10.1016/j.clinthera.2018.02.001
98,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Carer Enablement,,Telephone (Nurse/AHP),,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
99,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
100,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
101,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
102,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Home Delivery/Order,-,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
103,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Disposal,-,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
104,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Routine,Reminders,Telephone,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
105,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Co-pay,Telephone,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
106,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Insurance support,Telephone,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
107,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Free-Supply,Telephone,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
108,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Motivation/Confidence,Coaching/Counseling,Inperson,,Adherence_MPR_mean,3.0,https://doi.org/10.1016/j.clinthera.2018.02.001
109,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
110,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
111,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
112,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
113,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Disposal,-,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
114,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Routine,Reminders,Telephone,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
115,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Co-pay,Telephone,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
116,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Insurance support,Telephone,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
117,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Motivation/Confidence,Coaching/Counseling,Inperson,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
118,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Carer Enablement,,Telephone (Nurse/AHP),,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
119,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
120,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
121,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
122,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Home Delivery/Order,-,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
123,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Disposal,-,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
124,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Routine,Reminders,Telephone,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
125,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Co-pay,Telephone,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
126,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Insurance support,Telephone,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
127,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Free-Supply,Telephone,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
128,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Motivation/Confidence,Coaching/Counseling,Inperson,,Adherence_MPR_gr80%,67.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
129,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Carer Enablement,,Telephone (Nurse/AHP),,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
130,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
131,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
132,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
133,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Home Delivery/Order,-,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
134,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Disposal,-,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
135,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Routine,Reminders,Telephone,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
136,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Co-pay,Telephone,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
137,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Insurance support,Telephone,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
138,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Free-Supply,Telephone,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
139,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Motivation/Confidence,Coaching/Counseling,Inperson,,Adherence_MPR_mean,33.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
140,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
141,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
142,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
143,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
144,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Home Delivery/Order,-,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
145,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Disposal,-,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
146,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Routine,Reminders,Telephone,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
147,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Co-pay,Telephone,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
148,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Insurance support,Telephone,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
149,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Free-Supply,Telephone,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
150,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Motivation/Confidence,Coaching/Counseling,Inperson,,Perc_Persistence,52.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
151,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Inperson,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
152,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
153,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Usage Support,Dose/inj training,Inperson,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
154,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Home Delivery/Order,-,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
155,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Disposal,-,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
156,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Routine,Reminders,Telephone,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
157,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Co-pay,Telephone,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
158,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Insurance support,Telephone,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
159,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Motivation/Confidence,Coaching/Counseling,Inperson,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
160,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Carer Enablement,,Telephone (Nurse/AHP),,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
161,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Inperson,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
162,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
163,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Usage Support,Dose/inj training,Inperson,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
164,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Home Delivery/Order,-,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
165,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Logistics,Disposal,-,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
166,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Medicine Routine,Reminders,Telephone,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
167,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Co-pay,Telephone,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
168,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Insurance support,Telephone,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
169,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Free-Supply,Telephone,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
170,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Motivation/Confidence,Coaching/Counseling,Inperson,,Perc_LowPain,16.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
171,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
172,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Website,Website,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
173,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,App,App,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
174,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Logistics,Home Delivery/Order,-,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
175,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
176,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
177,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
178,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
179,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Website,Website,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
180,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,App,App,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
181,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
182,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
183,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Inperson,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
184,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
185,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Website,Website,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
186,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,App,App,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
187,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Logistics,Home Delivery/Order,-,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
188,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
189,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,Dose/inj training,Inperson,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
190,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
191,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
192,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Website,Website,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
193,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,App,App,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
194,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Logistics,Home Delivery/Order,-,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
195,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
196,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
197,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
198,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Medicine Routine,Reminders,Email/SMS/Mail,,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
199,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Effective HCP Appointments,Patient care coordination,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
200,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Motivation/Confidence,ICP,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
201,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
202,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Psychosocial-Emotional,Patient communities-support,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
203,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Financial,Co-pay,Telephone,,Adherence_MPR_gr80%,31.0,https://doi.org/10.3111/13696998.2012.744316
204,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence,11.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
205,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence,11.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
206,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Logistics,Home Delivery/Order,Telephone,,Perc_Persistence,11.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
207,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Effective HCP Appointments,Patient care coordination,Telephone,,Perc_Persistence,11.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
208,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Inperson,,Perc_discontinuation,37.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
209,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation,37.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
210,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Usage Support,Dose/inj training,Inperson,,Perc_discontinuation,37.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
211,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Logistics,Home Delivery/Order,Telephone,,Perc_discontinuation,37.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
212,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Effective HCP Appointments,Patient care coordination,Telephone,,Perc_discontinuation,37.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
213,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence_12mnth,8.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
214,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence_12mnth,8.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
215,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Logistics,Home Delivery/Order,Telephone,,Perc_Persistence_12mnth,8.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
216,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Effective HCP Appointments,Patient care coordination,Telephone,,Perc_Persistence_12mnth,8.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
217,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Inperson,,Perc_discontinuation_12mnth,40.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
218,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,40.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
219,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Usage Support,Dose/inj training,Inperson,,Perc_discontinuation_12mnth,40.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
220,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Medicine Logistics,Home Delivery/Order,Telephone,,Perc_discontinuation_12mnth,40.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
221,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Effective HCP Appointments,Patient care coordination,Telephone,,Perc_discontinuation_12mnth,40.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
222,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
223,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
224,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Effective HCP Appointments,Patient care coordination,Telephone,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
225,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,ICP,Telephone,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
226,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
227,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,,Email/SMS/Mail,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
228,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Psychosocial-Emotional,Patient communities-support,Email/SMS/Mail,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
229,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Financial,Co-pay,Telephone,,Perc_Persistence_12mnth,,https://doi.org/10.1080/03007995.2021.1918072
230,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
231,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
232,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Effective HCP Appointments,Patient care coordination,Telephone,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
233,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,ICP,Telephone,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
234,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
235,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,,Email/SMS/Mail,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
236,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Psychosocial-Emotional,Patient communities-support,Email/SMS/Mail,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
237,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Financial,Co-pay,Telephone,,Perc_Persistence_6mnth,,https://doi.org/10.1080/03007995.2021.1918072
238,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Medicine Routine,Reminders,Email/SMS/Mail,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
239,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Effective HCP Appointments,Patient care coordination,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
240,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,ICP,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
241,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
242,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,,Email/SMS/Mail,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
243,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Psychosocial-Emotional,Patient communities-support,Email/SMS/Mail,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
244,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Financial,Co-pay,Telephone,,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
245,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Medicine Routine,Reminders,Email/SMS/Mail,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
246,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Effective HCP Appointments,Patient care coordination,Telephone,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
247,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
248,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Psychosocial-Emotional,Patient communities-support,Email/SMS/Mail,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
249,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
250,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Medicine Routine,Reminders,Email/SMS/Mail,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
251,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,Coaching/Counseling,Telephone,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
252,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,,Email/SMS/Mail,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
253,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Psychosocial-Emotional,Patient communities-support,Email/SMS/Mail,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
254,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Financial,Co-pay,Telephone,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
255,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
256,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
257,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
258,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
259,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
260,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
261,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
262,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
263,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
264,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
265,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
266,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
267,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,PREM: Satisfaction_mean,,https://doi.org/10.2147/PPA.S293941
268,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
269,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
270,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
271,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
272,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
273,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
274,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
275,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
276,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
277,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
278,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
279,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
280,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
281,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
282,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
283,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
284,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
285,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
286,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
287,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
288,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
289,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
290,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
291,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
292,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,Perc_Persistence_24mnth,38.0,https://doi.org/10.2147/PPA.S293941
293,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
294,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Welcome Pack,Welcome Pack,,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
295,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
296,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
297,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
298,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
299,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Motivation/Confidence,ICP,Telephone,,Perc_Discontinuation_24mnth,67.0,https://doi.org/10.2147/PPA.S293941
300,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence_6mnth,77.0,https://doi.org/10.1002/osp4.419
301,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,Website,Website,,Perc_Persistence_6mnth,77.0,https://doi.org/10.1002/osp4.419
302,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,,Email/SMS/Mail,,Perc_Persistence_6mnth,77.0,https://doi.org/10.1002/osp4.419
303,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Medicine Routine,Reminders,Telephone,,Perc_Persistence_6mnth,77.0,https://doi.org/10.1002/osp4.419
304,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_6mnth,77.0,https://doi.org/10.1002/osp4.419
305,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence_6mnth,77.0,https://doi.org/10.1002/osp4.419
306,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,Website,Website,,Perc_Discontinuation_6mnth,53.0,https://doi.org/10.1002/osp4.419
307,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,,Email/SMS/Mail,,Perc_Discontinuation_6mnth,53.0,https://doi.org/10.1002/osp4.419
308,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Medicine Routine,Reminders,Telephone,,Perc_Discontinuation_6mnth,53.0,https://doi.org/10.1002/osp4.419
309,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Discontinuation_6mnth,53.0,https://doi.org/10.1002/osp4.419
310,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Discontinuation_6mnth,53.0,https://doi.org/10.1002/osp4.419
311,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,Nurse/AHP assistance,Inperson,,Weight_Loss_perc,43.0,https://doi.org/10.1002/osp4.419
312,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,Website,Website,,Weight_Loss_perc,43.0,https://doi.org/10.1002/osp4.419
313,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,,Email/SMS/Mail,,Weight_Loss_perc,43.0,https://doi.org/10.1002/osp4.419
314,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Medicine Routine,Reminders,Telephone,,Weight_Loss_perc,43.0,https://doi.org/10.1002/osp4.419
315,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Motivation/Confidence,Coaching/Counseling,Telephone,,Weight_Loss_perc,43.0,https://doi.org/10.1002/osp4.419
316,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Medicine Usage Support,Dose/inj training,Inperson,,Weight_Loss_perc,43.0,https://doi.org/10.1002/osp4.419
317,53,Other chronic conditions,Opioid dependence (OD),buprenorphine medicationassisted treatment (B-MAT),,USA,1426,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,15.0,https://doi.org/10.1016/j.addbeh.2012.01.013
318,53,Other chronic conditions,Opioid dependence (OD),buprenorphine medicationassisted treatment (B-MAT),,USA,1426,Medicine Routine,Reminders,Telephone,,Perc_Persistence_12mnth,15.0,https://doi.org/10.1016/j.addbeh.2012.01.013
319,53,Other chronic conditions,Opioid dependence (OD),buprenorphine medicationassisted treatment (B-MAT),,USA,1426,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_12mnth,15.0,https://doi.org/10.1016/j.addbeh.2012.01.013
320,53,Other chronic conditions,Opioid dependence (OD),buprenorphine medicationassisted treatment (B-MAT),,USA,1426,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,43.0,https://doi.org/10.1016/j.addbeh.2012.01.013
321,53,Other chronic conditions,Opioid dependence (OD),buprenorphine medicationassisted treatment (B-MAT),,USA,1426,Medicine Routine,Reminders,Telephone,,Perc_discontinuation_12mnth,43.0,https://doi.org/10.1016/j.addbeh.2012.01.013
322,53,Other chronic conditions,Opioid dependence (OD),buprenorphine medicationassisted treatment (B-MAT),,USA,1426,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_discontinuation_12mnth,43.0,https://doi.org/10.1016/j.addbeh.2012.01.013
323,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Patient Education,Website,Website,16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
324,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Medicine Routine,Reminders,Email/SMS/Mail,16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
325,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Psychosocial-Emotional,Patient communities-support,Partner Orgs,16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
326,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Financial,Insurance support,Telephone,16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
327,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,HCP-Needs,Approval/Administrative support,Telephone,16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
328,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
329,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Patient Education,Website,Website,16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
330,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Medicine Routine,Reminders,Email/SMS/Mail,16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
331,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Effective HCP Appointments,Patient care coordination,Telephone,16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
332,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Psychosocial-Emotional,Patient communities-support,Partner Orgs,16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
333,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Financial,Insurance support,Telephone,16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
334,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Patient Education,Welcome Pack,Welcome Pack,,PROM: Readmission,33.0,doi: 10.1097/WON.0000000000000395
335,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PROM: Readmission,33.0,doi: 10.1097/WON.0000000000000395
336,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,SideEffects/Comobidities Support,Welcome Pack,Welcome Pack,,PROM: Readmission,33.0,doi: 10.1097/WON.0000000000000395
337,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Medicine Routine,Reminders,Telephone,,PROM: Readmission,33.0,doi: 10.1097/WON.0000000000000395
338,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Motivation/Confidence,Coaching/Counseling,Telephone,,PROM: Readmission,33.0,doi: 10.1097/WON.0000000000000395
339,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Medicine Logistics,Pharmacy support,Telephone,,PROM: Readmission,33.0,doi: 10.1097/WON.0000000000000395
340,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PROM: ER Visits,43.0,doi: 10.1097/WON.0000000000000395
341,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,SideEffects/Comobidities Support,Welcome Pack,Welcome Pack,,PROM: ER Visits,43.0,doi: 10.1097/WON.0000000000000395
342,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Medicine Routine,Reminders,Telephone,,PROM: ER Visits,43.0,doi: 10.1097/WON.0000000000000395
343,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Medicine Logistics,Pharmacy support,Telephone,,PROM: ER Visits,43.0,doi: 10.1097/WON.0000000000000395
344,49,Other chronic conditions,Knee osteoarthritis,Care program,NA,Australia,1945,HCP-Needs,Effective HCP Appointments,Website,,PROM: Avg_Pain_improvemnt_12mth,65.0,https://doi.org/10.1016/j.ocarto.2021.100175
345,49,Other chronic conditions,Knee osteoarthritis,Care program,NA,Australia,1945,HCP-Needs,HCP/AHP training,Inperson,,PROM: Avg_Pain_improvemnt_12mth,65.0,https://doi.org/10.1016/j.ocarto.2021.100175
346,49,Other chronic conditions,Knee osteoarthritis,Care program,NA,Australia,1945,Patient Education,Nurse/AHP assistance,Inperson,,PROM: Avg_Pain_improvemnt_12mth,65.0,https://doi.org/10.1016/j.ocarto.2021.100175
347,6,Diabetes,Diabetes,NA,NA,USA,9051,Patient Education,App,App,,Perc_Persistence_6mnth,,https://doi.org/10.1016/j.invent.2014.10.001
348,6,Diabetes,Diabetes,NA,NA,USA,9051,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",App,,Perc_Persistence_6mnth,,https://doi.org/10.1016/j.invent.2014.10.001
349,6,Diabetes,Diabetes,NA,NA,USA,9051,Medicine Routine,Reminders,App,,Perc_Persistence_6mnth,,https://doi.org/10.1016/j.invent.2014.10.001
350,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
351,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Patient Education,Website,Website,,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
352,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Patient Education,,Email/SMS/Mail,,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
353,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Medicine Usage Support,Dose/inj training,Inperson,,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
354,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
355,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Financial,Co-pay,Telephone,,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
356,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
357,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Patient Education,Website,Website,,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
358,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Patient Education,,Email/SMS/Mail,,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
359,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Medicine Usage Support,Dose/inj training,Inperson,,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
360,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
361,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
362,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
363,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,,Email/SMS/Mail,,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
364,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
365,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
366,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,Website,Website,,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
367,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,,Email/SMS/Mail,,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
368,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,Welcome Pack,Welcome Pack,,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
369,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Medicine Usage Support,Dose/inj training,Inperson,,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
370,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
371,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Motivation/Confidence,Coaching/Counseling,Telephone,,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
372,9,Diabetes,Diabetes,NA,NA,USA,163,Patient Education,App,App,,Mean_Glycated_hem_change_12mnths,71.0,DOI: 10.2337/dc11-0366 
373,9,Diabetes,Diabetes,NA,NA,USA,163,Patient Education,Website,Website,,Mean_Glycated_hem_change_12mnths,71.0,DOI: 10.2337/dc11-0366 
374,9,Diabetes,Diabetes,NA,NA,USA,163,Motivation/Confidence,Coaching/Counseling,App,,Mean_Glycated_hem_change_12mnths,71.0,DOI: 10.2337/dc11-0366 
375,10,Diabetes,Diabetes,NA,NA,UK,137,Medicine Usage Support,Telemonitoring,Website,,HbA1c,8.0,https://doi.org/10.1258/jtt.2009.003006
376,11,Diabetes,Diabetes,Hypoglycaemic agent (OHA) and/or insulin,"Oral, SC",India,215,Patient Education,,Email/SMS/Mail,,HbA1c_less_8%,14.0,https://pubmed.ncbi.nlm.nih.gov/22616337/
377,11,Diabetes,Diabetes,Hypoglycaemic agent (OHA) and/or insulin,"Oral, SC",India,215,Motivation/Confidence,,Email/SMS/Mail,,HbA1c_less_8%,14.0,https://pubmed.ncbi.nlm.nih.gov/22616337/
378,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,Patient Education,Welcome Pack,Welcome Pack,,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
379,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
380,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,SideEffects/Comobidities Support,Welcome Pack,Welcome Pack,,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
381,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,SideEffects/Comobidities Support,AHPs services,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
382,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Telephone,,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
383,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,Patient Education,Welcome Pack,Welcome Pack,,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
384,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
385,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,SideEffects/Comobidities Support,Welcome Pack,Welcome Pack,,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
386,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,SideEffects/Comobidities Support,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
387,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Telephone,,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
388,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,HCP-Needs,Medicine Usage Support,Telephone,,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
389,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,HCP-Needs,PSP feedback,Telephone,,Perc_discontinuation,91.0,https://doi.org/10.1007/s12325-015-0183-7
390,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_6mnth,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
391,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Telephone,,Perc_Persistence_6mnth,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
392,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Medicine Routine,Reminders,Telephone,,Perc_Persistence_6mnth,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
393,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,SideEffects/Comobidities Support,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_6mnth,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
394,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Medicine Logistics,Home Delivery/Order,Telephone,,Perc_Persistence_6mnth,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
395,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
396,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Telephone,,Adherence,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
397,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,SideEffects/Comobidities Support,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
398,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Medicine Logistics,Home Delivery/Order,Telephone,,Adherence,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
399,16,Respiratory,Asthma,NA,NA,USA,3748,HCP-Needs,HCP/AHP training,Inperson,,Adherence_guidelines,152.0,https://doi.org/10.1016/j.jpeds.2004.12.017
400,16,Respiratory,Asthma,NA,NA,USA,3748,HCP-Needs,Medicine Usage Support,Inperson,,Adherence_guidelines,152.0,https://doi.org/10.1016/j.jpeds.2004.12.017
401,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Drug administration,Inperson,,Adherence_PDC_mean,15.0,https://doi.org/10.2147/PPA.S148777
402,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_PDC_mean,15.0,https://doi.org/10.2147/PPA.S148777
403,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_PDC_gr80%,19.0,https://doi.org/10.2147/PPA.S148777
404,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Drug administration,Inperson,,Adherence_PDC_gr80%,19.0,https://doi.org/10.2147/PPA.S148777
405,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Persistence,20.0,https://doi.org/10.2147/PPA.S148777
406,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Drug administration,Inperson,,Perc_Persistence,20.0,https://doi.org/10.2147/PPA.S148777
407,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Dose/inj training,Inperson,,Perc_Persistence,20.0,https://doi.org/10.2147/PPA.S148777
408,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Drug administration,Inperson,,Perc_discontinuation,15.0,https://doi.org/10.2147/PPA.S148777
409,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Dose/inj training,Inperson,,Perc_discontinuation,15.0,https://doi.org/10.2147/PPA.S148777
410,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Patient Education,Nurse/AHP assistance,Inperson,,Hospitalisation_rate,26.0,https://doi.org/10.2147/PPA.S148777
411,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Dose/inj training,Inperson,,Hospitalisation_rate,26.0,https://doi.org/10.2147/PPA.S148777
412,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Patient Education,Nurse/AHP assistance,Inperson,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
413,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Usage Support,Dose/inj training,Inperson,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
414,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Logistics,Home Delivery/Order,-,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
415,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Logistics,Disposal,-,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
416,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Routine,Reminders,Telephone,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
417,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Financial,Co-pay,Telephone,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
418,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Financial,Insurance support,Telephone,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
419,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Financial,Free-Supply,Telephone,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
420,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Motivation/Confidence,Coaching/Counseling,Inperson,,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
421,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Patient Education,Nurse/AHP assistance,Inperson,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
422,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
423,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Usage Support,Dose/inj training,Inperson,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
424,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Logistics,Home Delivery/Order,-,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
425,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Routine,Reminders,Telephone,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
426,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Financial,Insurance support,Telephone,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
427,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Motivation/Confidence,Coaching/Counseling,Inperson,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
428,22,Autoimmune diseases,Ulcerative colitis,Mesalamine,Oral,USA,21,Medicine Routine,Reminders,Telephone,,Adherence,34.0,https://doi.org/10.1016/j.crohns.2009.10.002
429,22,Autoimmune diseases,Ulcerative colitis,Mesalamine,Oral,USA,21,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence,34.0,https://doi.org/10.1016/j.crohns.2009.10.002
430,22,Autoimmune diseases,Ulcerative colitis,Mesalamine,Oral,USA,21,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Refill_rate_6mnth,15.0,https://doi.org/10.1016/j.crohns.2009.10.002
431,22,Autoimmune diseases,Ulcerative colitis,Mesalamine,Oral,USA,21,Medicine Routine,Reminders,Telephone,,Refill_rate_6mnth,15.0,https://doi.org/10.1016/j.crohns.2009.10.002
432,24,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,174,Patient Education,Nurse/AHP assistance,Inperson,,PROM: MS QoL,18.0,https://doi.org/10.1097/JNN.0000000000000100
433,24,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,174,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PROM: MS QoL,18.0,https://doi.org/10.1097/JNN.0000000000000100
434,24,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,174,Medicine Usage Support,Dose/inj training,Inperson,,PROM: MS QoL,18.0,https://doi.org/10.1097/JNN.0000000000000100
435,25,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Germany,731,Patient Education,Nurse/AHP assistance,Inperson,,Medical_costs_reduction_euro,100.0,https://doi.org/10.1186/s12883-015-0426-x
436,25,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Germany,731,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Medical_costs_reduction_euro,100.0,https://doi.org/10.1186/s12883-015-0426-x
437,25,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Germany,731,Medicine Usage Support,Dose/inj training,Inperson,,Medical_costs_reduction_euro,100.0,https://doi.org/10.1186/s12883-015-0426-x
438,25,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Germany,731,Motivation/Confidence,Coaching/Counseling,Inperson,,Medical_costs_reduction_euro,100.0,https://doi.org/10.1186/s12883-015-0426-x
439,27,Neurology,Multiple sclerosis,"Interferon beta-1a, Interferon beta-1b, Glatiramer acetate, Mitoxantrone, and Natalizumab",SC,USA,3125,Medicine Routine,Reminders,Telephone,,Adherence_MPR_improvement,100.0,https://doi.org/10.1177/1352458510373487
440,27,Neurology,Multiple sclerosis,"Interferon beta-1a, Interferon beta-1b, Glatiramer acetate, Mitoxantrone, and Natalizumab",SC,USA,3125,Medicine Logistics,Home Delivery/Order,Telephone,,Adherence_MPR_improvement,100.0,https://doi.org/10.1177/1352458510373487
441,27,Neurology,Multiple sclerosis,"Interferon beta-1a, Interferon beta-1b, Glatiramer acetate, Mitoxantrone, and Natalizumab",SC,USA,3125,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence_MPR_improvement,100.0,https://doi.org/10.1177/1352458510373487
442,28,Neurology,Multiple sclerosis,"Interferon beta, Dimethyl fumarate, Glatiramer acetate, Teriflunomide, and Fingolimod",SC,Israel,62,Psychosocial-Emotional,e-diary/patient story,App,,Adherence_MPR_gr80%,3.0,https://doi.org/10.1177/2055217320939309
443,30,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Sweden,46,Medicine Routine,Reminders,Telephone,,Adherence,22.0,https://doi.org/10.1371/journal.pone.0218453
444,30,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Sweden,46,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,22.0,https://doi.org/10.1371/journal.pone.0218453
445,30,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Sweden,46,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence,22.0,https://doi.org/10.1371/journal.pone.0218453
446,30,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Sweden,46,Psychosocial-Emotional,e-diary/patient story,App,,Adherence,22.0,https://doi.org/10.1371/journal.pone.0218453
447,31,Neurology,Multiple sclerosis,Fingolimod,Oral,Switzerland,70,Patient Education,Nurse/AHP assistance,Inperson,,Qualitative only,,https://doi.org/10.1186/s12913-020-05278-3
448,32,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,1123,Medicine Routine,Reminders,Telephone,93.0,PROM: EQ-5D VAS Score,26.0,https://doi.org/10.1097/JNN.0b013e31828a4161
449,32,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,1123,Medicine Usage Support,Dose/inj training,Inperson,32.0,PROM: EQ-5D VAS Score,26.0,https://doi.org/10.1097/JNN.0b013e31828a4161
450,32,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,1123,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),45.0,PROM: EQ-5D VAS Score,26.0,https://doi.org/10.1097/JNN.0b013e31828a4161
451,32,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,1123,Patient Education,Nurse/AHP assistance,Inperson,32.0,PROM: EQ-5D VAS Score,26.0,https://doi.org/10.1097/JNN.0b013e31828a4161
452,33,Neurology,Multiple sclerosis,Interferon beta-1a,SC,USA,435,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_discontinuation,86.0,https://doi.org/10.1331/1544345054475469
453,33,Neurology,Multiple sclerosis,Interferon beta-1a,SC,USA,435,Patient Education,Help-line (non-clinical),Telephone,,Perc_discontinuation,86.0,https://doi.org/10.1331/1544345054475469
454,34,Neurology,Multiple sclerosis,"Interferon-β, glatiramer acetate",SC,Germany,93,Patient Education,Nurse/AHP assistance,Inperson,,Achieved_informed_choice,195.0,https://doi.org/10.1097/JNN.0000000000000100
455,34,Neurology,Multiple sclerosis,"Interferon-β, glatiramer acetate",SC,Germany,93,Patient Education,Welcome Pack,Welcome Pack,,Achieved_informed_choice,195.0,https://doi.org/10.1097/JNN.0000000000000100
456,35,Neurology,Multiple sclerosis,NA,,Belgium,191,Patient Education,Nurse/AHP assistance,Inperson,,Impact of disease severity on PSP outcome,,DOI: 10.3233/NRE-130975
457,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Patient Education,Help-line (non-clinical),Telephone,,Perc_Persistence_12mnth,11.0,https://doi.org/10.1007/s11657-018-0487-8
458,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Patient Education,Help-line (non-clinical),Telephone,,Perc_discontinuation_12mnth,23.0,https://doi.org/10.1007/s11657-018-0487-8
459,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_discontinuation_12mnth,23.0,https://doi.org/10.1007/s11657-018-0487-8
460,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Patient Education,Help-line (non-clinical),Telephone,,Adherence_gr75%,12.0,https://doi.org/10.1007/s11657-018-0487-8
461,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Motivation/Confidence,Coaching/Counseling,Telephone,,Adherence_gr75%,12.0,https://doi.org/10.1007/s11657-018-0487-8
462,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Medicine Routine,Reminders,Email/SMS/Mail,,Adherence_gr75%,12.0,https://doi.org/10.1007/s11657-018-0487-8
463,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_6mnth,47.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
464,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Medicine Routine,Reminders,Telephone,,Perc_Persistence_6mnth,47.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
465,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Patient Education,Welcome Pack,Welcome Pack,,Perc_Persistence_6mnth,47.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
466,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Discontinuation_6mnth,31.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
467,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,10.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
468,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Medicine Routine,Reminders,Telephone,,Adherence,10.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
469,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Patient Education,Welcome Pack,Welcome Pack,,Adherence,10.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
470,38,Other chronic conditions,Osteoporosis,Denosumab,SC,Canada,1793,Medicine Routine,Reminders,Telephone,,Perc_Persistence_12mnth,,http://dx.doi.org/10.1185/03007995.2015.1053049
471,38,Other chronic conditions,Osteoporosis,Denosumab,SC,Canada,1793,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,,http://dx.doi.org/10.1185/03007995.2015.1053049
472,38,Other chronic conditions,Osteoporosis,Denosumab,SC,Canada,1793,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_discontinuation_12mnth,,http://dx.doi.org/10.1185/03007995.2015.1053049
473,38,Other chronic conditions,Osteoporosis,Denosumab,SC,Canada,1793,Medicine Routine,Reminders,Telephone,,Perc_discontinuation_12mnth,,http://dx.doi.org/10.1185/03007995.2015.1053049
474,38,Other chronic conditions,Osteoporosis,Denosumab,SC,Canada,1793,Patient Education,Welcome Pack,Welcome Pack,,Perc_discontinuation_12mnth,,http://dx.doi.org/10.1185/03007995.2015.1053049
475,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),62.0,Perc_Persistence_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
476,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,Patient Education,Welcome Pack,Welcome Pack,62.0,Perc_Persistence_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
477,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,HCP-Needs,PSP feedback,Email/SMS/Mail,62.0,Perc_Persistence_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
478,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),62.0,Perc_Discontinuation_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
479,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,HCP-Needs,PSP feedback,Email/SMS/Mail,62.0,Perc_Discontinuation_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
480,42,Other chronic conditions,Osteoporosis,Teriparatide,SC,Netherlands,1573,Motivation/Confidence,,Email/SMS/Mail,,Perc_Discontinuation_24mnth,21.0,https://doi.org/10.1007/s00198-019-05052-0
481,42,Other chronic conditions,Osteoporosis,Teriparatide,SC,Netherlands,1573,Psychosocial-Emotional,Patient-segmentation,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,21.0,https://doi.org/10.1007/s00198-019-05052-0
482,42,Other chronic conditions,Osteoporosis,Teriparatide,SC,Netherlands,1573,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,21.0,https://doi.org/10.1007/s00198-019-05052-0
483,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,,https://doi.org/10.1185/03007995.2013.851659
484,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Usage Support,Dose/inj training,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,,https://doi.org/10.1185/03007995.2013.851659
485,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Routine,Reminders,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,,https://doi.org/10.1185/03007995.2013.851659
486,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,,https://doi.org/10.1185/03007995.2013.851659
487,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Usage Support,Dose/inj training,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,,https://doi.org/10.1185/03007995.2013.851659
488,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Routine,Reminders,Telephone (Nurse/AHP),,Perc_Discontinuation_24mnth,,https://doi.org/10.1185/03007995.2013.851659
489,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,,https://doi.org/10.1185/03007995.2013.851659
490,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Usage Support,Dose/inj training,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,,https://doi.org/10.1185/03007995.2013.851659
491,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Logistics,Home Delivery/Order,-,,PREM: Satisfaction_mean,,https://doi.org/10.1185/03007995.2013.851659
492,44,Other chronic conditions,Osteoporosis,Risedronate,Oral,"Australia, North and South America, Europe, and Africa",2382,Medicine Usage Support,Testing,-,,Perc_Persistence_12mnth,4.0,https://doi.org/10.1210/jc.2006-1526
493,44,Other chronic conditions,Osteoporosis,Risedronate,Oral,"Australia, North and South America, Europe, and Africa",2382,Medicine Usage Support,Testing,-,,Perc_discontinuation_12mnth,13.0,https://doi.org/10.1210/jc.2006-1526
494,45,Other chronic conditions,High blood pressure,Telmisartan,Oral,Poland,398,Medicine Routine,Reminders,Email/SMS/Mail,,Compliance,6.0,10.1097/HJH.0b013e328331b718
495,45,Other chronic conditions,High blood pressure,Telmisartan,Oral,Poland,398,Medicine Usage Support,Telemonitoring,Website,,Compliance,6.0,10.1097/HJH.0b013e328331b718
496,46,Other chronic conditions,Chronic health conditions,NA,,Australia,254,Motivation/Confidence,Goal Setting,Telephone (Nurse/AHP),,PREM: NPS,15.0,10.1097/HJH.0b013e328331b718
497,46,Other chronic conditions,Chronic health conditions,NA,,Australia,254,Motivation/Confidence,Goal Setting,Telephone (Nurse/AHP),,PROM: Health_Improvement,0.0,10.1097/HJH.0b013e328331b718
498,48,Other chronic conditions,Growth hormone deficiency (GHD),Somatropin,SC,Argentina,80,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_median,13.0,10.1097/HJH.0b013e328331b718
499,48,Other chronic conditions,Growth hormone deficiency (GHD),Somatropin,SC,Argentina,80,Medicine Usage Support,Telemonitoring,Website,,Adherence_median,13.0,10.1097/HJH.0b013e328331b718
500,48,Other chronic conditions,Growth hormone deficiency (GHD),Somatropin,SC,Argentina,80,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_MPR_gr80%,100.0,10.1097/HJH.0b013e328331b718
501,48,Other chronic conditions,Growth hormone deficiency (GHD),Somatropin,SC,Argentina,80,Medicine Usage Support,Telemonitoring,Website,,Adherence_MPR_gr80%,100.0,10.1097/HJH.0b013e328331b718
502,3,Cancer,Prostate cancer,NA,NA,Australia,75,Psychosocial-Emotional,Psychological Intervention,Website,,PROM: DASS-21_normal,,https://doi.org/10.1016/j.invent.2014.10.001
503,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Medicine Logistics,Home Delivery/Order,-,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
504,17,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1952,Financial,Free-Supply,Telephone,,Persistence_DaysOnTh,30.0,https://link.springer.com/article/10.1007/s40744-021-00309-9
505,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
506,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_Persistence_12mnth,11.0,https://doi.org/10.2147/PPA.S59496
507,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Logistics,Home Delivery/Order,-,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
508,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Perc_Persistence_24mnth,23.0,https://doi.org/10.2147/PPA.S59496
509,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Perc_discontinuation_12mnth,41.0,https://doi.org/10.2147/PPA.S59496
510,23,Neurology,Multiple sclerosis,IFN β-1a,SC,Republic of Ireland,2884,Medicine Usage Support,"Dose support (inc. Induction, FDO, Titration)",Inperson,,Perc_Discontinuation_24mnth,38.0,https://doi.org/10.2147/PPA.S59496
511,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_gr80%,,https://doi.org/10.3111/13696998.2012.744316
512,29,Neurology,Multiple sclerosis,Glatiramer acetate (Copaxone),SC,USA,5825,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_MPR_gr80%,43.0,https://doi.org/10.3111/13696998.2012.744316
513,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence,11.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
514,39,Other chronic conditions,Osteoporosis,Teriparatide,SC,Italy,382,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,8.0,https://link.springer.com/article/10.1007/s00223-012-9574-9
515,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_gr80%,,https://doi.org/10.1080/03007995.2021.1918072
516,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
517,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,ICP,Telephone,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
518,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,,Email/SMS/Mail,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
519,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Financial,Co-pay,Telephone,,Adherence_MPR_mean,,https://doi.org/10.1080/03007995.2021.1918072
520,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,PREM: Adapted_BIPQ_BMQ_%MRisk,,https://doi.org/10.2147/PPA.S293941
521,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Carer Enablement,,Telephone (Nurse/AHP),,Perc_Persistence_12mnth,22.0,https://doi.org/10.2147/PPA.S293941
522,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,Medicine Routine,Reminders,Telephone,,Perc_discontinuation_12mnth,71.0,https://doi.org/10.2147/PPA.S293941
523,52,Other chronic conditions,Obesity,Liraglutide 3.0 mg,SC,Canada,119,Patient Education,Nurse/AHP assistance,Inperson,,Perc_Discontinuation_6mnth,53.0,https://doi.org/10.1002/osp4.419
524,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
525,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,HCP-Needs,Approval/Administrative support,Telephone,16.0,Adherence_PDC_gr80%,,https://doi.org/10.1080/03007995.2018.1536651
526,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Patient Education,Welcome Pack,Welcome Pack,,PROM: ER Visits,43.0,doi: 10.1097/WON.0000000000000395
527,54,Other chronic conditions,Ostomy surgery,Surgery,NA,USA,433,Motivation/Confidence,Coaching/Counseling,Telephone,,PROM: ER Visits,43.0,doi: 10.1097/WON.0000000000000395
528,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_discontinuation,40.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
529,7,Diabetes,Diabetes,Insulin glargine,SC,USA,544,Financial,Co-pay,Telephone,,Adherence,180.0,http://dx.doi.org/10.1136/bmjdrc-2018-000593
530,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,Welcome Pack,Welcome Pack,,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
531,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
532,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Non_compliance_6month,23.0,https://doi.org/10.2337/diaclin.29.1.17
533,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,HCP-Needs,PSP feedback,Telephone,,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
534,14,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,Canada,308,Medicine Routine,Reminders,Telephone,,Adherence,,https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1428
535,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Dose/inj training,Inperson,,Adherence_PDC_gr80%,19.0,https://doi.org/10.2147/PPA.S148777
536,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Patient Education,Nurse/AHP assistance,Inperson,,Perc_discontinuation,15.0,https://doi.org/10.2147/PPA.S148777
537,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,14.0,https://doi.org/10.18553/jmcp.2017.16272
538,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Medicine Logistics,Disposal,-,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
539,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Financial,Co-pay,Telephone,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
540,20,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,USA,1199,Financial,Free-Supply,Telephone,,Medical_costs_disease_$,22.0,https://doi.org/10.18553/jmcp.2017.16272
541,22,Autoimmune diseases,Ulcerative colitis,Mesalamine,Oral,USA,21,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence,34.0,https://doi.org/10.1016/j.crohns.2009.10.002
542,25,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Germany,731,Motivation/Confidence,Coaching/Counseling,Telephone,,Medical_costs_reduction_euro,100.0,https://doi.org/10.1186/s12883-015-0426-x
543,27,Neurology,Multiple sclerosis,"Interferon beta-1a, Interferon beta-1b, Glatiramer acetate, Mitoxantrone, and Natalizumab",SC,USA,3125,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Adherence_MPR_improvement,100.0,https://doi.org/10.1177/1352458510373487
544,30,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Sweden,46,Medicine Usage Support,Dose/inj training,Telephone,,Adherence,22.0,https://doi.org/10.1371/journal.pone.0218453
545,30,Neurology,Multiple sclerosis,Interferon beta-1a,SC,Sweden,46,Patient Education,,Email/SMS/Mail,,Adherence,22.0,https://doi.org/10.1371/journal.pone.0218453
546,31,Neurology,Multiple sclerosis,Fingolimod,Oral,Switzerland,70,Motivation/Confidence,Coaching/Counseling,Inperson,,Qualitative only,,https://doi.org/10.1186/s12913-020-05278-3
547,32,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,1123,Motivation/Confidence,Coaching/Counseling,Telephone,45.0,PROM: EQ-5D VAS Score,26.0,https://doi.org/10.1097/JNN.0b013e31828a4161
548,32,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,1123,Psychosocial-Emotional,Patient communities-support,Website,56.0,PROM: EQ-5D VAS Score,26.0,https://doi.org/10.1097/JNN.0b013e31828a4161
549,33,Neurology,Multiple sclerosis,Interferon beta-1a,SC,USA,435,Patient Education,,Email/SMS/Mail,,Perc_discontinuation,86.0,https://doi.org/10.1331/1544345054475469
550,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Medicine Routine,Reminders,Email/SMS/Mail,,Perc_Persistence_12mnth,11.0,https://doi.org/10.1007/s11657-018-0487-8
551,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Medicine Routine,Reminders,Telephone,,Perc_Discontinuation_6mnth,31.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
552,38,Other chronic conditions,Osteoporosis,Denosumab,SC,Canada,1793,Patient Education,Welcome Pack,Welcome Pack,,Perc_Persistence_12mnth,,http://dx.doi.org/10.1185/03007995.2015.1053049
553,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,Medicine Usage Support,Dose/inj training,Inperson,62.0,Perc_Persistence_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
554,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,Patient Education,Welcome Pack,Welcome Pack,62.0,Perc_Discontinuation_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
555,41,Other chronic conditions,Osteoporosis,Teriparatide,SC,France,5413,Medicine Usage Support,Dose/inj training,Inperson,62.0,Perc_Discontinuation_6mnth,80.0,https://doi.org/10.1007/s00198-008-0698-8
556,42,Other chronic conditions,Osteoporosis,Teriparatide,SC,Netherlands,1573,Motivation/Confidence,,Email/SMS/Mail,,Perc_Persistence_24mnth,8.0,https://doi.org/10.1007/s00198-019-05052-0
557,42,Other chronic conditions,Osteoporosis,Teriparatide,SC,Netherlands,1573,Psychosocial-Emotional,Patient-segmentation,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,8.0,https://doi.org/10.1007/s00198-019-05052-0
558,42,Other chronic conditions,Osteoporosis,Teriparatide,SC,Netherlands,1573,Patient Education,Nurse/AHP assistance,Telephone (Nurse/AHP),,Perc_Persistence_24mnth,8.0,https://doi.org/10.1007/s00198-019-05052-0
559,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Logistics,Home Delivery/Order,-,,Perc_Persistence_24mnth,,https://doi.org/10.1185/03007995.2013.851659
560,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Logistics,Home Delivery/Order,-,,Perc_Discontinuation_24mnth,,https://doi.org/10.1185/03007995.2013.851659
561,43,Other chronic conditions,Osteoporosis,Teriparatide,SC,Spain,23069,Medicine Routine,Reminders,Telephone (Nurse/AHP),,PREM: Satisfaction_mean,,https://doi.org/10.1185/03007995.2013.851659
562,46,Other chronic conditions,Chronic health conditions,NA,,Australia,254,Motivation/Confidence,ICP,Telephone (Nurse/AHP),,PREM: NPS,15.0,10.1097/HJH.0b013e328331b718
563,46,Other chronic conditions,Chronic health conditions,NA,,Australia,254,Motivation/Confidence,ICP,Telephone (Nurse/AHP),,PROM: Health_Improvement,0.0,10.1097/HJH.0b013e328331b718
564,21,Autoimmune diseases,"Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Hidradenitis Suppurativa, Psoriatic Arthritis, Ankylosing Spondylitis",Adalimumab,SC,Canada,38840,Financial,Free-Supply,Telephone,,Perc_Dispensed Rx,56.0,https://doi.org/10.1016/j.clinthera.2018.02.001
565,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Effective HCP Appointments,Patient care coordination,Telephone,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
566,50,Other chronic conditions,Major depressive disorder,Vortioxetine,Oral,USA,1931,Motivation/Confidence,ICP,Telephone,,HEDIS AMM 180days,33.0,https://doi.org/10.1080/03007995.2021.1918072
567,51,Other chronic conditions,Neovascular age-related macular degeneration (nAMD),Aflibercept,IVI,Australia,4000,SideEffects/Comobidities Support,Tools-Kits,Telephone,,PREM: Decrease_Concern_%,,https://doi.org/10.2147/PPA.S293941
568,55,Other chronic conditions,Schizophrenia,Aripiprazole,SC,USA,234,Effective HCP Appointments,Patient care coordination,Telephone,16.0,Adherence_PDC,,https://doi.org/10.1080/03007995.2018.1536651
569,8,Diabetes,Diabetes,Pramlintide,SC,USA,233,Patient Education,Website,Website,,Perc_Discontinuation_6mnth,17.0,https://doi.org/10.2337/diaclin.29.1.17
570,9,Diabetes,Diabetes,NA,NA,USA,163,Patient Education,,Email/SMS/Mail,,Mean_Glycated_hem_change_12mnths,71.0,DOI: 10.2337/dc11-0366 
571,13,Idiopathic pulmonary fibrosis,Idiopathic pulmonary fibrosis,Pirfenidone,Oral,United Kingdom; Austria,534,HCP-Needs,Medicine Usage Support,Telephone,,PREM: Satisfaction_mean,40.0,https://doi.org/10.1007/s12325-015-0183-7
572,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Patient Education,Nurse/AHP assistance,Inperson,,Adherence_PDC_mean,15.0,https://doi.org/10.2147/PPA.S148777
573,19,Autoimmune diseases,Crohn’s disease,Certolizumab,SC,USA,420,Medicine Usage Support,Drug administration,Inperson,,Hospitalisation_rate,26.0,https://doi.org/10.2147/PPA.S148777
574,22,Autoimmune diseases,Ulcerative colitis,Mesalamine,Oral,USA,21,Motivation/Confidence,Coaching/Counseling,Telephone,,Refill_rate_6mnth,15.0,https://doi.org/10.1016/j.crohns.2009.10.002
575,24,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,174,Patient Education,Welcome Pack,Welcome Pack,,PROM: MS QoL,18.0,https://doi.org/10.1097/JNN.0000000000000100
576,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_Persistence_12mnth,11.0,https://doi.org/10.1007/s11657-018-0487-8
577,36,Other chronic conditions,Osteoporosis,Teriparatide,SC,Japan,790,Motivation/Confidence,Coaching/Counseling,Telephone,,Perc_discontinuation_12mnth,23.0,https://doi.org/10.1007/s11657-018-0487-8
578,37,Other chronic conditions,Osteoporosis,Bisphosphonate ibandronate,SC,UK,561,Patient Education,Welcome Pack,Welcome Pack,,Perc_Discontinuation_6mnth,31.0,https://doi.org/10.1111/j.1742-1241.2006.01059.x
579,24,Neurology,Multiple sclerosis,Interferon beta-1b,SC,Germany,174,Medicine Routine,Reminders,Telephone,,PROM: MS QoL,18.0,https://doi.org/10.1097/JNN.0000000000000100
